Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Syndax Announces Participation at Three Upcoming Investor Conferences

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.23 (+1.50%)
Syndax Announces Participation in BTIG Virtual Biotechnology Conference

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.23 (+1.50%)
iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair

, /PRNewswire/ -- iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has appointed Dr. ...

SNDX : 14.23 (+1.50%)
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN)...

SNDX : 14.23 (+1.50%)
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.23 (+1.50%)
Portage is pleased to announce the appointment of Allan L. Shaw as CFO

, /PRNewswire/ - Portage Biotech Inc. (PBT.U: CSE, PTGEF: OTC Markets) ("Portage" or the "Company") a leader in the early stage immune oncology space announced today the appointment of to Chief Financial...

NEWLF : 0.0001 (unch)
PTGEF : 9.9920 (+2.48%)
SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

SNDX : 14.23 (+1.50%)
HTGC : 11.62 (+1.22%)
Syndax Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.23 (+1.50%)
Syndax Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.23 (+1.50%)
Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.23 (+1.50%)
Syndax Announces Proposed Public Offering of Common Stock

, /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced...

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presents preclinical...

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations...

SNDX : 14.23 (+1.50%)
Will Syndax Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss

Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 14.23 (+1.50%)
Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 14.23 (+1.50%)
HTGC : 11.62 (+1.22%)
Plug Power (PLUG) to Report Q4 Earnings: What to Expect?

Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.

FTR : 0.2600 (+11.02%)
PLUG : 13.34 (+1.37%)
SNDX : 14.23 (+1.50%)
NGM : 15.78 (-2.05%)
Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it...

SNDX : 14.23 (+1.50%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar